The earnings call reflected a positive sentiment overall, driven by significant revenue growth, advancements in COVID-19 vaccines, and progress within the oncology pipeline. However, there were concerns regarding increased operating costs and contractual disputes. The financial guidance being at the lower end of the range was a noted challenge.

Company Guidance

In the third quarter of 2024, BioNTech reported revenues of approximately EUR 1.245 billion, a significant increase from the EUR 895 million achieved in the same period last year, largely due to the early approvals of their variant-adapted COVID-19 vaccines. The company's cost of sales amounted to EUR 179 million, while R&D expenses rose to EUR 550 million, reflecting progress in clinical trials for oncology pipeline candidates. SG&A expenses decreased to EUR 151 million, and other operating results were negatively impacted by EUR 355 million due to accruals for contractual disputes. BioNTech reported a net income of EUR 198 million, with diluted earnings per share of EUR 0.81, and maintained a robust cash position of EUR 17.8 billion. The company adjusted its full-year revenue guidance to the lower end of its previous range, citing risks of write-downs and other charges, and decreased its SG&A and capital expenditures guidance by EUR 100 million each, while maintaining its R&D expense guidance.

Significant Revenue Growth

BioNTech reported total revenues of approximately EUR 1.245 billion for Q3 2024, compared to EUR 895 million for the same period in 2023, marking a significant increase attributed to early approvals of variant-adapted COVID-19 vaccines.

COVID-19 Vaccine Advancements

Successfully launched updated COVID-19 vaccines targeting latest variants, with distribution underway globally. Early strain recommendations and approvals enabled timely delivery for vaccination campaigns.

Progress in Oncology Pipeline

Advancements in bispecific immunomodulator BNT327 and mRNA cancer vaccine portfolio, including successful trials in triple-negative breast cancer and small cell lung cancer.

Strong Financial Position

BioNTech's cash and cash equivalents plus security investments reached approximately EUR 17.8 billion as of September 30, 2024, supporting continued investment in R&D.

Innovation in AI Capabilities

Showcased in-house AI company, InstaDeep, highlighting BioNTech's commitment to state-of-the-art AI in medical research and development.

---

BioNTech SE (BNTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BNTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 10, 2025	2024 (Q4)	0.50 / -	1.9	―	―	―
Nov 04, 2024	2024 (Q3)	-1.61 / 0.85	0.704	20.90% (+0.15)
Aug 05, 2024	2024 (Q2)	-2.12 / -3.53	-0.83	-325.32% (-2.70)
May 06, 2024	2024 (Q1)	-1.31 / -1.38	2.153	-163.90% (-3.53)
Mar 20, 2024	2023 (Q4)	2.49 / 2.00	9.725	-79.48% (-7.73)
Nov 06, 2023	2023 (Q3)	-0.62 / 0.70	7.33	-90.40% (-6.63)
Aug 07, 2023	2023 (Q2)	-0.87 / -0.83	6.774	-112.25% (-7.60)
May 08, 2023	2023 (Q1)	0.28 / 2.15	14.955	-85.60% (-12.80)
Mar 27, 2023	2022 (Q4)	8.17 / 9.72	12.791	-23.97% (-3.07)
Nov 07, 2022	2022 (Q3)	3.59 / 7.33	12.97	-43.48% (-5.64)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

BNTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2024	$111.48	$108.97	-2.25%
Aug 05, 2024	$82.01	$78.36	-4.45%
May 06, 2024	$92.72	$93.35	+0.68%
Mar 20, 2024	$94.12	$90.00	-4.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---